Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
myfortic magasýruþolin tafla 360 mg
novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 360 mg
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
mykofenolatmofetil actavis filmuhúðuð tafla 500 mg
actavis group ptc ehf. - mycophenolatum mofetil - filmuhúðuð tafla - 500 mg
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
xylocain adrenalin stungulyf, lausn 10 mg/ml+5 míkróg/ml
aspen pharma trading limited - lidocainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 10 mg/ml+5 míkróg/ml
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
xylocain dental adrenalin stungulyf, lausn 20 mg/ml+12,5 míkróg/ml
dentsply detrey gmbh* - adrenalinum bítartrat (epinephrinum bítartrat); lidocainum hýdróklóríð - stungulyf, lausn - 20 mg/ml+12,5 míkróg/ml
Umoja wa Ulaya -
Kiaisilandi -
EMA (European Medicines Agency)
pedmarqsi
fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - Öll önnur lækningavörur - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.